Select language:
On this page


    Prescription under medical supervision


    Therapeutic action

    • Long-lasting lactation inhibitor


    • Inhibition of lactation or suppression of established lactation in case of intrauterine foetal death or neonatal death

    Forms and strengths

    • 0.5 mg scored tablet

    Dosage and duration

    Lactation inhibition

    • 1 mg single dose on the first day post-partum


    Lactation suppression

    • 0.25 mg every 12 hours for 2 days

    Contra-indications, adverse effects, precautions

    • Do not administer to patients with postpartum hypertension or psychosis, preeclampsia, valvulopathy, and history of pulmonary, retroperitoneal or pericardial fibrosis.
    • May cause: hypotension, valvulopathy, dizziness, headache, nausea, drowsiness, hallu cinations.
    • Do not combine with chlorpromazine, haloperidol, metoclopramide, promethazine (effect of cabergoline antagonised), methylergometrine (risk of vasoconstriction and hypertensive crisis), and macrolides (effect of cabergoline increased).
    • Pregnancy: CONTRA-INDICATED


    • The use of cabergoline is not recommended to inhibit lactation in women who chose to not breastfeed: it is not justified to expose women to the adverse effects of cabergoline, lactation will stop spontaneously.
    • Cabergoline is not included in the WHO list of essential medicines.
    • Cabergoline is a dopamine agonist also used in the treatment of Parkinson’s disease.


    – Below 25 °C